Literature DB >> 10683511

Alterations in cytokine but not chemokine mRNA expression during three distinct Theiler's virus infections.

D J Theil1, I Tsunoda, J E Libbey, T J Derfuss, R S Fujinami.   

Abstract

DA, GDVII and H101 are neurovirulent strains of Theiler's murine encephalomyelitis virus that cause very different neuropathology and CNS disease when inoculated into SJL/J mice. DA virus causes a chronic demyelinating disease, GDVII virus causes an acute fatal polioencephalomyelitis, and H101 virus causes an acute pachymeningitis with hydrocephalus. Performing RNase protection assays, we detected the same pattern of chemokine (RANTES, MCP-1, IP-10, MIP-1beta, MIP-1alpha and MIP-2) mRNA expression in brain and spinal cord during all three infections. In contrast, IFN-beta and IL-6 mRNA were highly expressed only in GDVII virus infection, whereas high levels of LT-alpha mRNA were only found during DA virus infection. Our study demonstrates that proinflammatory cytokines are involved in the neuropathogenesis of CNS disease and modulate the acute and chronic process underlying different pathologic features of disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10683511     DOI: 10.1016/s0165-5728(99)00251-9

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  29 in total

1.  Infection with Theiler's murine encephalomyelitis virus directly induces proinflammatory cytokines in primary astrocytes via NF-kappaB activation: potential role for the initiation of demyelinating disease.

Authors:  JoAnn P Palma; Daeho Kwon; Neil A Clipstone; Byung S Kim
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

2.  Neurotropic viral infections leading to epilepsy: focus on Theiler's murine encephalomyelitis virus.

Authors:  Jane E Libbey; Robert S Fujinami
Journal:  Future Virol       Date:  2011-11       Impact factor: 1.831

3.  Social disruption induced priming of CNS inflammatory response to Theiler's virus is dependent upon stress induced IL-6 release.

Authors:  E G Vichaya; E E Young; M A Frazier; J L Cook; C J Welsh; M W Meagher
Journal:  J Neuroimmunol       Date:  2011-10-13       Impact factor: 3.478

4.  Anti-CCL2 treatment inhibits Theiler's murine encephalomyelitis virus-induced demyelinating disease.

Authors:  William J Karpus; Kevin J Kennedy; Brian T Fife; Jamie L Bennett; Mauro C Dal Canto; Steven L Kunkel; Nicholas W Lukacs
Journal:  J Neurovirol       Date:  2006-08       Impact factor: 2.643

5.  Interleukin-6 as a mechanism for the adverse effects of social stress on acute Theiler's virus infection.

Authors:  Mary W Meagher; Robin R Johnson; Erin E Young; Elisabeth G Vichaya; Shannon Lunt; Elizabeth A Hardin; Marilyn A Connor; C Jane R Welsh
Journal:  Brain Behav Immun       Date:  2007-06-25       Impact factor: 7.217

6.  Three immune-mediated disease models induced by Theiler's virus: Multiple sclerosis, seizures and myocarditis.

Authors:  Ikuo Tsunoda; Fumitaka Sato; Seiichi Omura; Mitsugu Fujita; Namie Sakiyama; Ah-Mee Park
Journal:  Clin Exp Neuroimmunol       Date:  2016-10-25

7.  Infiltrating macrophages are key to the development of seizures following virus infection.

Authors:  Matthew F Cusick; Jane E Libbey; Dipan C Patel; Daniel J Doty; Robert S Fujinami
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

8.  The Biology of Persistent Infection: Inflammation and Demyelination following Murine Coronavirus Infection of the Central Nervous System.

Authors:  Martin P Hosking; Thomas E Lane
Journal:  Curr Immunol Rev       Date:  2009-05-04

Review 9.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  Emilia L Oleszak; J Robert Chang; Herman Friedman; Christos D Katsetos; Chris D Platsoucas
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

10.  TGF-beta1 suppresses T cell infiltration and VP2 puff B mutation enhances apoptosis in acute polioencephalitis induced by Theiler's virus.

Authors:  Ikuo Tsunoda; Jane E Libbey; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2007-09-04       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.